Please assess the completion status of the following clinical trial:

Trial Title: SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Premature infants between 600 and 900 grams birth weight~* Intubated and on mechanical ventilation~* Sustained (\>= 30 minutes) fraction of inspired oxygen (FiO₂) \>= 0.30 within 8 hours prior to randomization~Exclusion Criteria:~* Mother has prolonged rupture of membranes ≥ 2 weeks~* Culture-proven sepsis~* High grade intraventricular hemorrhage (IVH)~* Congenital heart disease~* Congential anomalies inconsistent with life or likely to confound efficacy or safety endpoints~* FiO₂≥ 0.80 and mean airway pressure (MAP) ≥ 12 cmH2O at day of life (DOL) 3~* FiO₂\< 0.25 at any time between meeting the entry criteria to immediately prior to randomization~* Concomitant use of any other surfactant within the first 48 hours of life~* Prior use of nitric oxide~* Prior use of steroids~* Current participation in any other clinical trial or has received an experimental drug or used an experimental device

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 10 Days
- Healthy Volunteers: f

Study Arms:
- SURFAXIN High Dose (Type: EXPERIMENTAL): SURFAXIN (lucinactant) at 175 mg/kg
- SURFAXIN Low Dose (Type: EXPERIMENTAL): SURFAXIN (lucinactant) at 90 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Sham air using 3.0 mL/kg volume of air

Based on this trial design, predict the completion outcome and termination type (if applicable).